Navigation Links
A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
Date:9/27/2010

PARSIPPANY, N.J., Sept. 27 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer Healthcare, a leader in helping smokers quit and the marketer of nicotine replacement therapy (NRT) products, including Nicorette® and NicoDerm® CQ®, supports the findings of the American Heart Association (AHA) policy statement regarding smokeless tobacco products.(1) GSK Consumer Healthcare agrees that these products should not be used as an alternative to cigarettes or for smoking cessation due to the potential negative health consequences and their impact on smoking behavior. 

The AHA statement is important because the U.S. Food and Drug Administration (FDA) has just finished accepting comments from the public on how FDA should regulate certain smokeless tobacco products.  GSK Consumer Healthcare submitted a comment to the FDA on the potential public health impact of oral dissolvable tobacco products.  In our submission, GSK Consumer Healthcare called for oral dissolvable tobacco products to be withdrawn from the market until their sponsors can demonstrate to FDA that their marketing is appropriate for the protection of public health.

The AHA policy statement, notes that smokeless tobacco products are not safe alternatives to smoking and are associated with heart attack, stroke and certain cancers.(1)  Also, due to the marketing of these products, smokeless tobacco products may also initiate further tobacco use and perpetuate smoking.(1) 

Tobacco use, including smokeless tobacco, is the largest cause of preventable death and disease in the world.(2)  More than 400,000 Americans die every year from tobacco-related disease.(2)  The only proven way to reduce these health consequences is to stop using tobacco completely.  Smokeless tobacco products are currently being marketed without clear evidence of their safety.

NRT products alternatively, have helped millions of people around the world quit smoking and, as a result, have significantly reduced their exposure to the risks of cancer and other smoking-related diseases.(3)  GlaxoSmithKline Consumer Healthcare believes that before considering a potential role for oral dissolvable tobacco products in reducing the adverse health effects of smoking, there are significant opportunities to enhance the impact of existing smoking cessation aids, including expanding access to and use of NRT products. While the FDA is the final authority on the labeling of NRT products sold in the U.S., GSK Consumer Healthcare is committed to continuing to work with medical and clinical experts, and the FDA, to ensure that consumers have the best possible chance to quit smoking.

Quitting smoking is the single most important step smokers can take to improve their health – and it's also one of the most difficult.  By developing innovative new products and support systems to improve the quit experience, and helping to make the products as accessible as possible, GSK Consumer Healthcare works to inspire and enable every smoker to quit for good.

  1. Piano, et al. Impact of Smokeless Tobacco Products on Cardiovascular Disease: Implications for Policy, Prevention, and Treatment. A Policy Statement From the American Heart Association. Circulation published online Sep 13, 2010. Available at http://circ.ahajournals.org/cgi/reprint/CIR.0b013e3181f432c3v1?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=smokeless+tobacco&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT.
  2. Centers for Disease Control and Prevention. Targeting Tobacco Use: The Nation's Leading Cause of Preventable Death. Available at http://www.cdc.gov/nccdphp/publications/aag/osh.htm.
  3. GSK data on file.


'/>"/>
SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine
2. Statement from CHPA on Todays FDA Advisory Committee Meeting on Dextromethorphan
3. Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics
4. Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta® to a Broader Pain Population
5. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
6. NCPA Statement on CVS Caremark-Aetna Agreement
7. GlaxoSmithKline Statement in Response to FDA Advisory Committees Vote on Safety of Avandia® (rosiglitazone)
8. Dendreon Statement on CMS National Coverage Analysis
9. NORD Calls for Statement of Policy on Orphan Drug Development
10. Teva Admits to Making False Statements in US Gianvi™ Label and Agrees to Corrective Measures
11. Alexza Pharmaceuticals Files Shelf Registration Statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for ... by age and sex in these markets. GD epidemiology report is written ... high quality, transparent and market-driven, providing expert analysis of disease trends in ... , Italy , Spain , ...
(Date:2/4/2016)... 4, 2016  The Senior Care Pharmacy Coalition ... Committee Chairman Jason Chaffetz (R-UT) and ... hearing , "Developments in the Prescription Drug ... growing questions about abusive pharmacy benefit manager (PBM) ... and Ranking Member Elijah Cummings (D-MD) are diligent, ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
Breaking Medicine Technology:
(Date:2/5/2016)... Francisco, CA (PRWEB) , ... February 05, 2016 ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, ... Dr. Cheng, CitiDent offers a complete range of oral health care, including general ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Calls Blacklist ... a completely new user interface design and the developer has fixed known bugs within ... they want to on their phone while not consuming any of their device’s battery ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... that Medicare San Luis Obispo users can expect to see in 2016. To view ... two most significant changes will directly impact many San Luis Obispo seniors who rely ...
(Date:2/4/2016)... ... February 04, 2016 , ... According to a recent ... see their dentist once every six months for a cleaning and checkup, depending on ... Dr. Farzad Feiz, head dentist at Calabasas Dental Group and California Dental Care, notes ...
Breaking Medicine News(10 mins):